Status: Recruiting
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following administration under fasting and fed conditions.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Jun 12, 2026Locations: 1
Eligibility criteria
Voluntarily and personally signed Informed Consent Form (ICF) by a participant o... [+41]
Subject's decision to discontinue participation in the study; [+12]